Big Cypress Acquisition Corp.

    Big Cypress Acquisition Corp.

    NNASDAQ:BCYP
    8.44
    USD
    -2.01
    (-19.23%)
    Big Cypress Acquisition Corp.
    NASDAQ:BCYP
    (Nasdaq Stock Market)

    Recent

    price

    8.44

    P/E

    ratio

    - -

    div

    yld

    - -

    ROIC.AI

    No data availableFinancial data will appear here once available

    Capital Structure

    FRC

    •

    in mil. unless spec.
    No data availableFinancial data will appear here once available

    Working Capital

    FRC

    •

    in mil. unless spec.
    No data availableFinancial data will appear here once available

    Growth Rates

    FRC

    •

    in mil. unless spec.
    No data availableFinancial data will appear here once available

    Quarterly Revenue

    FRC

    •

    in mil. unless spec.
    No data availableFinancial data will appear here once available

    Quarterly Earnings Per Share

    FRC

    •

    in mil. unless spec.
    No data availableFinancial data will appear here once available

    Quarterly Dividends Per Share

    FRC

    •

    in mil. unless spec.
    No data availableFinancial data will appear here once available
    Similar Companies
    Business

    Company News

    • Big Cypress Acquisition (OTCMKTS:BCYP) Shares Cross Above 50 Day Moving Average – Should You Sell?

    • Big Cypress Acquisition (OTCMKTS:BCYP) Stock Price Crosses Below 200 Day Moving Average – Time to Sell?

    • Big Cypress Acquisition (OTCMKTS:BCYP) Shares Pass Below Two Hundred Day Moving Average – What’s Next?

    • Big Cypress Acquisition (OTCMKTS:BCYP) Shares Pass Below 200-Day Moving Average – Here’s What Happened

    • Analyzing Inhibikase Therapeutics (NYSE:IKT) and Big Cypress Acquisition (OTCMKTS:BCYP)

    • Big Cypress Acquisition (OTCMKTS:BCYP) Stock Price Crosses Above 50-Day Moving Average – Here’s Why

    • Comparing Inhibikase Therapeutics (NYSE:IKT) and Big Cypress Acquisition (OTCMKTS:BCYP)

    • Big Cypress Acquisition (OTCMKTS:BCYP) Shares Cross Below Fifty Day Moving Average – Here’s Why

    • SAB Biotherapeutics Announces SAB-185 Receives Positive DSMB Review and Advances to Phase 3 in NIH-Sponsored ACTIV-2 Trial for Treatment of COVID-19

    • Big Cypress Acquisition Corp Announces Special Meeting of Stockholders to Approve Business Combination with SAB Biotherapeutics

    • SAB Biotherapeutics Awarded Additional $60.5M from BARDA and U.S. Department of Defense for Rapid Response Capability and Advancing SAB-185 for Treatment of COVID-19

    • SAB Biotherapeutics Announces Completion of Enrollment in Phase 2a Challenge Trial of SAB-176 for the Treatment of Seasonal Influenza

    • SAB Biotherapeutics Announces Nonclinical Data Demonstrating SAB-185 Potently Neutralizes Delta and Lambda SARS-CoV-2 Variants

    • SAB Biotherapeutics to Present at the Ladenburg Thalmann Annual Healthcare Conference 2021

    • SAB Biotherapeutics Announces Publication of Preclinical Data Demonstrating SAB-185 Effectively Neutralizes SARS-CoV-2 Variants

    • Big Cypress Acquisition Corp. Announces Confidential Submission of S-4 Registration Statement Related to Proposed Business Combination with SAB Biotherapeutics

    • SAB Biotherapeutics to List on Nasdaq through Merger with Big Cypress Acquisition Corp., Advancing Unique Human Antibody Platform with Demonstrated Utility in Immunotherapy and Rapid Response to Emerging Diseases